济民健康管理股份有限公司 独立董事专门会议工作细则 第一章 总 则 第一条 为完善公司治理结构，规范独立董事专门会议议事方式和决策程 序，促使并保障独立董事有效地履行职责，充分发挥独立董事在公司内部治理中 的作用，根据《上市公司独立董事管理办法》及其他有关法律法规的规定，结合 公司实际情况，制定本工作细则。 第二条 独立董事专门会议（以下简称"专门会议"）是指全部由公司独 立 董事参加，为履行独立董事职责专门召开的会议。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、上海证 券交易所业务规则和《济民健康管理股份有限公司章程》（以下简称"公司章程"） 的规定，认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用， 维护公司整体利益，保护中小股东合法权益。 第二章 专门会议的职责权限 第四条 下列事项应当经独立董事专门会议讨论并经全体独立董事过半数 同意后，方可提交董事会审议： （一）应当披露的关联交易； （二）公司及相关方变更或者豁免承诺的方案； （三）公司董事会针对公司被收购所作出的决策及采取的措施； （四）法律、行 ...

Core Insights - The medical device sector experienced a rise of 0.57% on November 12, with Tianyi Medical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Device Sector Performance - Tianyi Medical (301097) closed at 65.30, up 11.34% with a trading volume of 46,500 and a transaction value of 294 million [1] - Jimin Health (603222) closed at 11.33, up 10.00% with a trading volume of 729,500 and a transaction value of 797 million [1] - Zhongyuan Xiehe (600645) closed at 28.61, up 10.00% with a trading volume of 311,400 and a transaction value of 857 million [1] - Other notable gainers include Danah Biotechnology (920009) up 9.99%, Lideman (300289) up 9.89%, and Yipeng Medical (300753) up 8.21% [1] Capital Flow Analysis - The medical device sector saw a net inflow of 739 million from institutional investors, while retail investors experienced a net outflow of 923 million [2][3] - Jimin Health had a net inflow of 205 million from institutional investors, but a net outflow of 138 million from retail investors [3] - Zhongyuan Xiehe also saw a net inflow of 194 million from institutional investors, with a significant net outflow of 932 million from retail investors [3]

Group 1 - The cell immunotherapy concept has seen a rise of 2.20%, making it the top-performing sector, with 43 stocks increasing in value [1][2] - Notable gainers include Kaineng Health, which hit a 20% limit up, and other companies like Nanjing Xinbai, Jimin Health, and Zhongyuan Qihe also reached their daily limit up [1] - The top gainers in percentage terms include Sanyuan Gene (up 12.45%), Guanhao Biological (up 7.47%), and Chengda Pharmaceutical (up 6.34%) [1] Group 2 - The cell immunotherapy sector attracted a net inflow of 1.465 billion yuan, with 38 stocks receiving net inflows, and 6 stocks exceeding 100 million yuan in net inflow [2] - Zhongyuan Qihe led the net inflow with 220 million yuan, followed by Jimin Health (209 million yuan), Hengrui Pharmaceutical (192 million yuan), and Nanjing Xinbai (176 million yuan) [2][3] - The net inflow ratios for Nanjing Xinbai, Jimin Health, and Zhongyuan Qihe were 34.82%, 26.18%, and 25.74% respectively, indicating strong investor interest [3]

Core Viewpoint - The market experienced a slight decline with the Shanghai Composite Index dropping 0.07%, while defensive sectors such as pharmaceuticals and oil & gas showed strength amidst a broader market downturn [1] Market Performance - The total trading volume in the Shanghai and Shenzhen markets was 1.95 trillion, a decrease of 48.6 billion compared to the previous trading day [1] - Over 3,500 stocks in the market experienced declines, indicating a broad market weakness [1] Sector Analysis - Defensive sectors collectively performed well, with the oil and gas sector seeing significant gains, leading to stocks like PetroChina and Zhenhua Oil reaching their daily limit [1] - The pharmaceutical sector continued to rise, particularly in cell immunotherapy, with stocks such as Kaineng Health and Jimin Health hitting their daily limit [1] - The banking sector showed strong performance, with Agricultural Bank of China and Industrial and Commercial Bank of China both reaching historical highs [1] - The consumer sector was selectively active, with stocks like Sanyuan and Zhongrui achieving three consecutive trading limit increases, and Dongbai Group seeing four limit increases in six days [1] - The lithium battery sector experienced a late rally, with Tianji shares achieving three limit increases in four days [1] Declining Sectors - The superhard materials sector faced a collective decline, with World falling over 10% [1] - Sectors such as insurance, pharmaceuticals, and oil & gas saw the largest gains, while sectors like cultivated diamonds, photovoltaics, and controllable nuclear fusion experienced the largest declines [1]

Group 1 - The immunotherapy sector is experiencing a strong rebound, with companies like Zhongyuan Qihuo and Kaineng Health hitting the daily limit up [1] - Other companies in the sector, such as Jimin Health, Guanhao Bio, Chengda Pharmaceutical, Zexing Pharmaceutical, and Heyuan Bio, are also showing significant gains [1]

Group 1 - The cell immunotherapy sector experienced a significant rally in the afternoon, with Kaineng Health hitting a 20% limit up, and Jimin Health, Zhongyuan Qihe, and Nanjing Xinbai also previously reaching their limit up [1] - Sanyuan Gene saw an increase of over 10%, while Chengda Pharmaceutical and Sunshine Nuohe also followed the upward trend [1] - A recent research paper published in the journal Nature Biotechnology indicates that low-intensity ultrasound treatment can eliminate neurotoxic debris in the brains of mice induced with hemorrhagic stroke [1]

Core Viewpoint - The company, Jimin Health (603222), has stated that the number of shareholders at the end of each quarter will be disclosed in regular reports, and shareholders can request information for specific dates by providing proof of shareholding [1] Summary by Categories - **Shareholder Information Disclosure** - The company will disclose the number of shareholders at the end of each quarter in its periodic reports [1] - Shareholders wishing to obtain the number of shareholders for other specific dates must provide written documentation proving the type and quantity of shares held [1] - The company will verify the identity of shareholders before providing the requested information [1]

Core Points - Jimin Health's stock price increased by 2.08% on November 11, reaching 10.33 CNY per share, with a market capitalization of 5.424 billion CNY [1] - The company has seen a year-to-date stock price increase of 52.14%, with a recent 5-day increase of 3.20% and a 60-day increase of 45.90% [1] - Jimin Health has appeared on the trading leaderboard 13 times this year, with the latest occurrence on September 11, where it recorded a net purchase of 66.0795 million CNY [1][2] Financial Performance - For the period from January to September 2025, Jimin Health reported a revenue of 545 million CNY, a year-on-year decrease of 20.21%, and a net profit of -77.1504 million CNY, a decrease of 371.51% [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 10.7447 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, Jimin Health had 58,100 shareholders, an increase of 107% from the previous period, with an average of 9,035 circulating shares per shareholder, a decrease of 51.69% [2] Business Overview - Jimin Health, established on December 24, 1996, and listed on February 17, 2015, is primarily engaged in the research, production, and sales of medical devices, medical services, and large-volume intravenous products [1] - The company's revenue composition includes 52.07% from pharmaceutical manufacturing, 46.01% from medical services, 1.54% from pharmaceutical trading, and 0.38% from other sources [1] Industry Classification - Jimin Health is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, with involvement in innovative drugs, cell therapy, in vitro diagnostics, antigen testing, and medical devices [2]

Core Viewpoint - Jimin Health announced on November 5 that the company will consider share buybacks based on market conditions [2] Group 1 - The company is actively engaging with investors through an interactive platform [2] - The decision to repurchase shares will be contingent on market circumstances [2]

Group 1 - The company plans to leverage the innovative policies of the Boao Lecheng Pilot Zone in Hainan to enhance external cooperation [2] - The company aims to increase investment in the research and development of innovative drugs [2] - The company intends to develop the Boao International Hospital into a high-level clinical research center and translational medicine platform [2]